Page last updated: 2024-11-07

cynarine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cynarine: active principle of the artichoke; functions primarily as a cholagogue and choleretic and also as antilipemic agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,3-dicaffeoylquinic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,3-dicaffeoylquinic acid : An alkyl caffeate ester obtained by the formal condensation of hydroxy groups at positions 1 and 3 of ()-quinic acid with two molecules of trans-caffeic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281769
CHEMBL ID487258
CHEBI ID520
SCHEMBL ID42528
MeSH IDM0263214
PubMed CID205954
MeSH IDM0263214

Synonyms (75)

Synonym
AC-6022
plemocil
cinarine
listrocol
cynarine
30964-13-7
1,5-di-o-caffeoylquinic acid
chebi:520 ,
CHEMBL487258
cynaricine
chinasaeure-1,3-dikaffeesaeureester
3,4-dihydroxycinnamic acid, 1-carboxy-4,5-dihydroxy-1,3-cyclohexylene ester
1-o,3-o-bis(3,4-dihydroxycinnamoyl)chinasaeure
(1r,3r,4s,5r)-1,3-bis[[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-4,5-dihydroxycyclohexane-1-carboxylic acid
(1r,3r,4s,5r)-1,3-bis((3-(3,4-dihydroxyphenyl)acryloyl)oxy)-4,5-dihydroxycyclohexanecarboxylic acid
A820670
cas-30964-13-7
tox21_111176
dtxcid9029805
S3301
bdbm50369484
cynarine [inn]
phemocil
quinic acid 1,5-dicaffeic ester
caffeic acid 1-carboxy-4,5-dihydroxy-1,3-cyclohexylene ester
cyclohexanecarboxylic acid, 1,3-bis((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-4,5-dihydroxy-
1,5-dicaffeoylqunic acid
cinarin
AKOS015912727
1,3-dicqa
SCHEMBL42528
NCGC00274085-01
tox21_111176_1
85D81U9JAV ,
cyclohexanecarboxylic acid, 1,3-bis(((2e)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl)oxy)-4,5-dihydroxy-, (1r,3r,4s,5r)-
1-carboxy-4,5-dihydroxy-1,3-cyclohexylenebis-(3,4-dihydroxycinnamate)
cynarine [mart.]
cynarine [who-dd]
(1r,3r,4s,5r)-1,3-bis((3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl)oxy)-4,5-dihydroxycyclohexanecarboxylic acid
3,4-dihydroxycinnamic acid 1-carboxy-4,5-dihydroxy-1,3-cyclohexylene ester
(1r-(1.alpha.,3.alpha.,4.alpha.,5.beta.))-1,3-bis((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-4,5-dihydroxycyclohexanecarboxylic acid
cynarine [mi]
212891-05-9
(1r,3r,4s,5r)-1,3-bis{[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexane-1-carboxylic acid
Q-100389
1884-23-7
1,5-dicaffeoyl quinic acid
(1r,3r,4s,5r)-1,3-bis({[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy})-4,5-dihydroxycyclohexane-1-carboxylic acid
J-003723
cynarin, analytical standard
unii-85d81u9jav
1,3-dicaffeoylquinic acid, >=98% (hplc)
AS-74959
(1r-(1alpha,3alpha,4alpha,5beta))-1,3-bis((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-4,5-dihydroxycyclohexanecarboxylic acid
cynarine [inn:who-dd]
HY-N0359
CS-6280
Q1763092
BCP29379
cynarine;1,3-dicaffeoylquinic acid;1,5-dqa;1,5-dicaffeoylquinic acid
(1r,3r,4s,5r)-1,3-bis(((e)-3-(3,4-dihydroxyphenyl)acryloyl)oxy)-4,5-dihydroxycyclohexane-1-carboxylic acid
cyclohexanecarboxylic acid,1,3-bis[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-4,5-dihydroxy-,(1r,3r,4s,5r)-
(1r,3r,4s,5r)-1,3-bis((3-(3,4-dihydroxyphenyl)acryloyl)oxy)-4,5-dihydroxycyclohexanecarboxylicacid
1_5_dihydrocaffeoylquinic_acid
DTXSID301309674
cynarine (mart.)
1,3-dicaffeoylquinic acid (constituent of echinacea angustifolia root, echinacea pallida root, echinacea purpurea root and echinacea purpurea aerial parts)
cynarinum
1,3-dicaffeoylquinic acid
1,3-bis[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-4,5-dihydroxycyclohexane-1-carboxylic acid
FT-0686591
1,5-dqa
3,5-dicaffeoylquinic acid; 3,5-cqa
DTXSID10860455
1,3-bis{[3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexane-1-carboxylic acid

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" To characterize the pharmacokinetic and metabolic properties of 1,5-DCQA in rats following single intravenous administration (160 mg/kg), the plasma concentrations of 1,5-DCQA were measured by high-performance liquid chromatography (HPLC) and the metabolites formed in urine were identified by liquid chromatography-mass spectrometry (LC-MS) in parallel to diode-array detection (DAD)."( Pharmacokinetics and metabolism of 1,5-dicaffeoylquinic acid in rats following a single intravenous administration.
Dong, JX; Dou, GF; Meng, ZY; Tang, ZM; Yan, LP; Yang, B; Zou, LB, 2006
)
0.33
" Using the measured plasma concentrations of 1,5-DCQA and its active metabolites in five healthy volunteers, pharmacokinetic profiles of 1,5-DCQA and its active metabolites were evaluated, which supported the clinical pharmacokinetic studies successfully."( Simultaneous determination of 1,5-dicaffeoylquinic acid and its active metabolites in human plasma by liquid chromatography-tandem mass spectrometry for pharmacokinetic studies.
Dong, J; Dou, G; Gu, R; Meng, Z; Wang, J, 2007
)
0.34
" The validated LC-MS/MS method was successfully applied to phase II clinical pharmacokinetic study of 1,5-DCQA in patients."( An improved LC-MS/MS method for simultaneous determination of 1,5-dicaffeoylquinic acid and its active metabolites in human plasma and its application to a pharmacokinetic study in patients.
Dong, X; Dou, G; Ji, X; Liu, J; Meng, Z; Wu, Z; Yuan, D, 2010
)
0.36
" We conducted a phase I and pharmacokinetic study with the phenolic compound-enriched product extracted from Erigeron breviscapus, Erigerontis hydroxybenzenes injection (EHI), in healthy Chinese volunteers."( Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: results of a randomized phase I study in healthy Chinese volunteers.
Dai, GL; Fang, ZY; Ju, WZ; Liu, F; Liu, SJ; Wu, T; Xiong, NN; Zhang, J; Zhao, Y; Zhou, L, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
quinic acidA cyclitol carboxylic acid.
alkyl caffeate esterA cinnamate ester obtained by formal condensation of caffeic acid with any alkyl alcohol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency33.49830.000811.382244.6684AID686978
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency24.54540.01237.983543.2770AID1645841
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency26.60110.001024.504861.6448AID743212
Histone H2A.xCricetulus griseus (Chinese hamster)Potency21.97410.039147.5451146.8240AID1224845
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency0.66820.000627.21521,122.0200AID743202
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Integrase Human immunodeficiency virus 1IC50 (µMol)1.60000.00051.544310.0000AID91431
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (97)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID420055Inhibition of STAT5b SH2 domain at 200 uM2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains.
AID641626Inhibition of Mycobacterium tuberculosis RmlD assessed as inhibition of dTDP-beta-6-deoxy-L-lyxo-4-hexulose to dTDP-beta-L-rhamnose conversion at 10 ug/ml2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Novel inhibitors of Mycobacterium tuberculosis dTDP-6-deoxy-L-lyxo-4-hexulose reductase (RmlD) identified by virtual screening.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID106907Concentration that inhibits Human Immunodeficiency Virus Type 1 (HIV-1)-induced death of MT-2 cells1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID401476Cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 1 mg/ml after 30 hrs
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID91431Inhibitory activity against Human Immunodeficiency Virus Type 1 integrase (HIV-1 IN) in the disintegration assay.1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID338034Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamic pyruvate transaminase release at 0.01 mg/ml administered before 10 mins of carbon tetrachloride challenge mea
AID1397992Inhibition of adenylate cyclase in alpha-MSH-stimulated mouse B16-F1 cells assessed as reduction in cAMP-CREB signaling pathway-mediated TYR expression level at 25 uM after 48 to 72 hrs by Western blot analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Mechanism underlying inhibitory effect of six dicaffeoylquinic acid isomers on melanogenesis and the computational molecular modeling studies.
AID338033Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamic oxaloacetic transaminase release at 3 mg/ml administered before 10 mins of carbon tetrachloride challenge mea
AID338037Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamic pyruvate transaminase release at 3 mg/ml administered before 10 mins of carbon tetrachloride challenge measur
AID1176142Cytotoxicity against mouse RAW264.7 cells at 50 uM by MTT assay2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Anti-inflammatory components of Chrysanthemum indicum flowers.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID420054Inhibition of STAT3 SH2 domain at 200 uM2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1397989Inhibition of tyrosinase in mouse B16-F1 cell lysates assessed as reduction in melanin production at 25 uM using L-DOPA as substrate incubated for 30 mins followed by substrate addition measured after 30 mins2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Mechanism underlying inhibitory effect of six dicaffeoylquinic acid isomers on melanogenesis and the computational molecular modeling studies.
AID261131Inhibition of PMA plus ionomycin-induced IL2 secretion in Jurkat cells2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Immuno-suppressive effect of blocking the CD28 signaling pathway in T-cells by an active component of Echinacea found by a novel pharmaceutical screening method.
AID338043Effect on glutamic pyruvate transaminase activity at 3 mg/ml
AID1397991Inhibition of alpha-MSH-stimulated melanogenesis in mouse B16-F1 cells assessed as reduction in intracellular melanin production at 25 uM after 72 hrs relative to control2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Mechanism underlying inhibitory effect of six dicaffeoylquinic acid isomers on melanogenesis and the computational molecular modeling studies.
AID338040Effect on glutamate oxaloacetic transaminase activity at 3 mg/ml
AID1460719Neuroprotective activity in human SH-SY5Y cells assessed as reduction in hydrogen peroxide-induced cytotoxicity by measuring cell viability level at 10 uM (Rvb = 50.7+/- 2.6%)2017Journal of natural products, 04-28, Volume: 80, Issue:4
Neuroprotective Caffeoylquinic Acid Derivatives from the Flowers of Chrysanthemum morifolium.
AID338042Effect on glutamic pyruvate transaminase activity at 1 mg/ml
AID261129Inhibition of anti-CD3 plus anti-CD28-induced IL2 secretion in Jurkat cells2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Immuno-suppressive effect of blocking the CD28 signaling pathway in T-cells by an active component of Echinacea found by a novel pharmaceutical screening method.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID401472Antihepatotoxic activity against 1.5 hrs galactosamine pretreatment-induced cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.1 mg/ml after 30 hrs relative to control
AID401471Antihepatotoxic activity against 1.5 hrs galactosamine pretreatment-induced cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.01 mg/ml after 30 hrs relative to control
AID401474Cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.01 mg/ml after 30 hrs
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID401473Antihepatotoxic activity against 1.5 hrs galactosamine pretreatment-induced cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 1 mg/ml after 30 hrs relative to control
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1248399Inhibition of alpha-amylase (unknown origin) relative to control2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
From carbohydrates to drug-like fragments: Rational development of novel α-amylase inhibitors.
AID401475Cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.1 mg/ml after 30 hrs
AID1460718Neuroprotective activity in human SH-SY5Y cells assessed as reduction in glutamate-induced cytotoxicity at 10 uM relative to untreated control2017Journal of natural products, 04-28, Volume: 80, Issue:4
Neuroprotective Caffeoylquinic Acid Derivatives from the Flowers of Chrysanthemum morifolium.
AID104233Lethal dose (LD5) concentration inhibiting growth of MT-2 cells by 5%1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
AID1397990Cytotoxicity against mouse B16-F1 cells assessed as reduction in cell viability at 25 uM after 72 hrs by MTT assay2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Mechanism underlying inhibitory effect of six dicaffeoylquinic acid isomers on melanogenesis and the computational molecular modeling studies.
AID338032Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamic oxaloacetic transaminase release at 1 mg/ml administered before 10 mins of carbon tetrachloride challenge mea
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1397993Inhibition of adenylate cyclase in alpha-MSH-stimulated mouse B16-F1 cells assessed as reduction in cAMP-CREB signaling pathway-mediated DCT expression level at 25 uM after 48 to 72 hrs by Western blot analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Mechanism underlying inhibitory effect of six dicaffeoylquinic acid isomers on melanogenesis and the computational molecular modeling studies.
AID419928Inhibition of STAT1 SH2 domain at 200 uM2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1176146Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated TNFalpha production at 10 uM by ELISA2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Anti-inflammatory components of Chrysanthemum indicum flowers.
AID1460717Neuroprotective activity in human SH-SY5Y cells assessed as reduction in oxygen-glucose deprivation-induced cytotoxicity at 10 uM relative to untreated control2017Journal of natural products, 04-28, Volume: 80, Issue:4
Neuroprotective Caffeoylquinic Acid Derivatives from the Flowers of Chrysanthemum morifolium.
AID338031Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamic oxaloacetic transaminase release at 0.1 mg/ml administered before 10 mins of carbon tetrachloride challenge m
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID338030Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamic oxaloacetic transaminase release at 0.01 mg/ml administered before 10 mins of carbon tetrachloride challenge
AID1176144Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production at 0.4 to 10 uM after 24 hrs by Griess assay2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Anti-inflammatory components of Chrysanthemum indicum flowers.
AID419926Inhibition of LCK SH2 domain at 200 uM2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains.
AID261130Cytotoxic activity against Jurkat cells upto 500 ug/mL by MTT assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Immuno-suppressive effect of blocking the CD28 signaling pathway in T-cells by an active component of Echinacea found by a novel pharmaceutical screening method.
AID338036Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamate pyruvate transaminase release at 1 mg/ml administered before 10 mins of carbon tetrachloride challenge measu
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID338035Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamic pyruvate transaminase release at 0.1 mg/ml administered before 10 mins of carbon tetrachloride challenge meas
AID338039Effect on glutamate oxaloacetic transaminase activity at 1 mg/ml
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID419927Inhibition of SRC SH2 domain at 200 uM2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains.
AID1176148Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated TNFalpha production at 0.4 to 2 uM by ELISA2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Anti-inflammatory components of Chrysanthemum indicum flowers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (98)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (15.31)18.7374
1990's3 (3.06)18.2507
2000's20 (20.41)29.6817
2010's44 (44.90)24.3611
2020's16 (16.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.98%)5.53%
Trials1 (14.29%)5.53%
Reviews1 (0.98%)6.00%
Reviews0 (0.00%)6.00%
Case Studies1 (0.98%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other99 (97.06%)84.16%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]